Accordingly, the use of primary tumor gene expression profiles as a basis for CMS classification in the clinical trial cohorts likely impacted the analyses of associations to anti-EGFR versus anti-VEGF therapy response. The gene discussed is VEGFA; the disease is neoplasm.